PRMT6 and cancer: The CBP/p300-interacting transactivator with ED-rich tail 2 (CITED2) further suppresses the CSC markers and reduces the cancer stem cell population in NSCLC.536 Integrated transcriptome and protein-protein interaction studies revealed that the arginine methyltransferase PRMT6 can regulate stemness properties via MEK/ERK pathway in hepatocellular carcinoma.537 Zhu et al.538 performed Spearman correlation test using TCGA pan cancer data and found the KMT2 family genes to be associated with cancer stemness and drug sensitivity.